You are here Home Resources and guidance Sponsors JACE Pharma Pty Ltd Regulatory activities for this sponsor. Listen Print Share LinkedIn (Twitter) Facebook Email Loading... Type (-) Designation or determination (4) Australian public assessment report (AusPar) (4) Prescription medicine registration (4) ARTG (3) Prescription medicine decision summary (3) Cancellation by sponsor (1) Date 2024 (1) 2019 (1) 2018 (2) Search Filters applied:Designation or determinationClear all Sponsor content4 result(s) found, displaying 1 to 4 Notice for sebetralstat (JACE Pharma Pty Ltd) 2 August 2024 Designation or determination Orphan drug Notice for trientine tetrahydrochloride (JACE Pharma Pty Ltd) 3 July 2019 Designation or determination Orphan drug Notice for cenegermin (recombinant human nerve growth factor) (JACE Pharma Pty Ltd) 30 August 2018 Designation or determination Priority review Notice for cenegermin (JACE Pharma Pty Ltd) 23 May 2018 Designation or determination Orphan drug
Notice for trientine tetrahydrochloride (JACE Pharma Pty Ltd) 3 July 2019 Designation or determination Orphan drug
Notice for cenegermin (recombinant human nerve growth factor) (JACE Pharma Pty Ltd) 30 August 2018 Designation or determination Priority review